"10.1371_journal.pone.0129619","plos one","2015-06-08T00:00:00Z","Dennis G Moledina; Chirag R Parikh; Amit X Garg; Heather Thiessen-Philbrook; Jay L Koyner; Uptal D Patel; Prasad Devarajan; Michael G Shlipak; Steven G Coca; TRIBE-AKI Consortium","Section of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America; VA CT Healthcare System, West Haven, Connecticut, United States of America; Program of Applied Translational Research, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America; Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois, United States of America; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America; Division of Nephrology and Hypertension, Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States of America; Division of General Internal Medicine, San Francisco VA Medical Center, University of California, San Francisco, California, United States of America","Conceived and designed the experiments: DGM CRP SGC. Analyzed the data: DGM CRP SGC. Contributed reagents/materials/analysis tools: DGM CRP AXG JLK PD UDP MGS SGC HTP. Wrote the paper: DGM CRP AXG HTP JLK UDP PD MGS SGC.","1. Details of IL-18 patent: Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality, United States Patent number 7141382 issued on November 28, 2006. Inventors: Chirag R. Parikh and Charles L. Edelstein, Family ID: 37449883, Appl. No.: 10/964,201. 2. NGAL patents: Dr. Prasad Devarjan is named co-inventor on the NGAL patents. United States Patent Names (numbers): NGAL for reduction and amelioration of ischemic and nephrotoxic injuries (7776824), NGAL for reduction and amelioration of ischemic and nephrotoxic injuries (8247376), and High molecular weight NGAL as a biomarker for chronic kidney disease (8592170). 3. The plasma NGAL assays were donated by Biosite, Inc. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2015","06","Dennis G Moledina","DGM",10,TRUE,3,NA,3,9,TRUE,TRUE,TRUE,1,"10",TRUE
